Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP32 | ISIN: US74366E1029 | Ticker-Symbol: PGF
Tradegate
03.06.25 | 18:44
45,600 Euro
+0,88 % +0,400
1-Jahres-Chart
PROTAGONIST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTAGONIST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
45,00045,40010:45

Aktuelle News zur PROTAGONIST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
Di9 Analysts Assess Protagonist Therapeutics: What You Need To Know3
DiH.C. Wainwright bekräftigt Kaufempfehlung für Protagonist Therapeutics-Aktie1
DiH.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock2
PROTAGONIST THERAPEUTICS Aktie jetzt für 0€ handeln
DiClear Street lowers price target for Protagonist Therapeutics stock3
DiClear Street senkt Kursziel für Protagonist Therapeutics-Aktie3
DiBTIG maintains buy rating on Protagonist Therapeutics stock1
23.05.Protagonist Therapeutics: EPS verfehlt Schätzungen um 0,13 $ - Umsatz schlechter als erwartet1
21.05.Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025219NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...
► Artikel lesen
09.05.Protagonist Therapeutics: Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting274Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to demonstrate...
► Artikel lesen
06.05.Protagonist Therapeutics, Inc - 10-Q, Quarterly Report8
06.05.Protagonist Therapeutics, Inc - 8-K, Current Report3
06.05.Protagonist Therapeutics: Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update259Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call...
► Artikel lesen
23.04.Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025243NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the...
► Artikel lesen
16.04.Protagonist Therapeutics Reports Granting of Inducement Award295NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
► Artikel lesen
11.04.BTIG maintains Buy on Protagonist Therapeutics stock, $82 target3
10.04.Protagonist Therapeutics: Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill22884% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16ICONIC-LEAD is the first ever Phase 3 registrational...
► Artikel lesen
18.03.Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) - Best Biotech Stock for 2025?3
18.03.Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025271Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage...
► Artikel lesen
13.03.Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More10
11.03.PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study5
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1